We are live on ! Find out more
QNRX

Quoin Pharmaceuticals
QNRX

0 hedge funds and large institutions have $390K invested in Quoin Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

112% more capital invested

Capital invested by funds: $184K → $390K (+$206K)

100% less funds holding

Funds holding: 1 → 0 (-1)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
–
Holders Change
-1
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$177K
2
UBS Group
UBS Group
Switzerland
-$5K
3
TRCT
Tower Research Capital (TRC)
New York
-$2K

QNRX Hedge Fund Activity: Q1 2017 in Review

0 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Quoin Pharmaceuticals (QNRX) for Q1 2017, worth a combined $390K — up 112% from $184K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of QNRX and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest seller was Sabby Management, exiting entirely with an estimated $177K sold.

  • 0 institutional investors held Quoin Pharmaceuticals (QNRX) as of Q1 2017, down from 1 in Q4 2016.
  • Funds reported $390K of Quoin Pharmaceuticals stock for Q1 2017, up 112% quarter-over-quarter.
  • 0 funds opened new Quoin Pharmaceuticals positions in Q1 2017 and 1 closed out, a net change of -1 holder.
  • The largest Quoin Pharmaceuticals seller in Q1 2017 was Sabby Management, an estimated $177K sold.

Based on aggregated 13F filings for Q1 2017.